Luminal B Breast Cancer Prognosis

Luminal a tumors are associated with the most favorable prognosis.

Luminal b breast cancer prognosis.

According to the report hr positive cancers such as luminal cancers have higher survival. These groups help guide decisions about which treatments are best. This is the most common type of breast cancer figure 1 and tends to be slower growing and less aggressive than other subtypes. Luminal a cancers are low grade tend to grow slowly and have the best prognosis.

Of the 4 major subtypes luminal a tumors tend to have the best prognosis with fairly high survival rates and fairly low recurrence rates. Group 1 luminal a. The risk of recurrence and metastasis in patients with luminal b breast cancer during a 2 to 5 year period and after 5 years was still present but the risk in patients with non luminal breast. Luminal b breast cancer is hormone receptor.

Luminal a breast cancer is hormone receptor positive estrogen receptor and or progesterone receptor positive her2 negative and has low levels of the protein ki 67 which helps control how fast cancer cells grow. This study aimed to examine the prognostic factors of luminal b like breast cancer. Breast cancer groups include. Group 2 luminal b.

Luminal a breast cancers are likely to benefit from hormone therapy and may also benefit from chemotherapy. About 30 45 percent of breast cancers are luminal a tumors. Luminal tumor cells look like those of breast cancers that start in the inner luminal cells lining the mammary ducts. This group includes tumors that are er positive and pr positive but negative for her2.

Clinical data of 695 luminal b like breast cancer patients who had been treated in our hospital during the period of past 4 5 years were collected and analyzed. Estrogen receptor er progesterone receptor pgr antigen identified by monoclonal antibody ki 67 ki67 were immunohistochemically detected. A 2019 review of breast cancer treatments features survival rates for different types of breast cancer. In our study young patients with luminal b breast cancer had a 2 5 fold higher risk of death and 3 6 fold higher risk of relapse disease compared with the older counterpart luminal a her2 or triple negative had similar survival outcomes in the two age groups.